Pulmonary Arterial Hypertension News

Arena Pharmaceutical's Ralinepag Shows Promise in Treating PAH in Phase 2 Clinical Trial - Pulmonary Hypertension News



Arena Pharmaceutical's Ralinepag Shows Promise in Treating PAH in Phase 2 Clinical Trial 
Pulmonary Hypertension News
Change in pulmonary vascular resistance (PVR; used in calculations of blood pressure, blood flow in vessels supplying the lungs) was the measure used to assess the efficacy of the drug. Also, the 6-minute walk distance (6MWD, the distance walked in 6 ...

 


Pulmonary Arterial Hypertension Global Market 2017 Key Players,Share, Trend, Segmentation and Forecast to 2022 - Medgadget (blog)



Pulmonary Arterial Hypertension Global Market 2017 Key Players,Share, Trend, Segmentation and Forecast to 2022 
Medgadget (blog)
?Pulmonary Arterial Hypertension ? Market Insights, Epidemiology and Market Forecast ? 2025? report provides an overview of the disease and in depth research related to Pulmonary Arterial Hypertension for the 7MM (United States, Germany, France, Italy, ...

and more » 


Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the ... - Business Wire (press release)



Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the ... 
Business Wire (press release)
... successfully completed a pre-Investigational New Drug Application (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for its lead compound RP5063, which is being developed for the treatment of pulmonary arterial hypertension (PAH).

and more » 


Retrovirus May Play a Role in Development of Pulmonary Hypertension in Rats, Study Finds - Pulmonary Hypertension News



Retrovirus May Play a Role in Development of Pulmonary Hypertension in Rats, Study Finds 
Pulmonary Hypertension News
An inherited virus' shift from a dormant to an active mode appears to be linked to the development of pulmonary arterial hypertension in rats, a study reports. Scientists may be able to develop PAH therapies around the idea of preventing the human ...

 


Arena Pharmaceuticals Announces Late Breaking Presentation of Positive Phase 2 Results with Ralinepag in Patients ... - PR Newswire (press release)



Bibeypost.com
 
Arena Pharmaceuticals Announces Late Breaking Presentation of Positive Phase 2 Results with Ralinepag in Patients ... 
PR Newswire (press release)
Ralinepag (APD811) is an oral, next-generation, selective IP receptor agonist targeting the prostacyclin pathway and intended for the treatment of pulmonary arterial hypertension (PAH). Arena discovered and developed this drug candidate internally.
Arena Pharma (ARNA) Announces Late Breaking Presentation of Positive Phase 2 Results with Ralinepag in Patients ... StreetInsider.com
Financial Analysis: Arena Pharmaceuticals (ARNA) versus Its Competitors StockNewsTimes
(ARNA) With Shares Trading unchanged at $27.56 Arena Pharmaceuticals Announces Late? First News 24
BZ Weekly 
all 40 news articles » 


Patients with Abnormal Blood Vessel Condition at Risk of Pulmonary Hypertension, Study Reports - Pulmonary Hypertension News



Patients with Abnormal Blood Vessel Condition at Risk of Pulmonary Hypertension, Study Reports 
Pulmonary Hypertension News
The condition develops due to high cardiac volume, or the amount of blood the heart pumps. It can lead to failure of the left side of the heart. In rare cases, HHT patients can develop pre-capillary hypertension, also known as pulmonary arterial ...

 


Chronic Thromboembolic PH Diagnosis and Management Update: Expert Q&A - The Cardiology Advisor



The Cardiology Advisor
 
Chronic Thromboembolic PH Diagnosis and Management Update: Expert Q&A 
The Cardiology Advisor
Of the 5 different types of pulmonary hypertension (PH), chronic thromboembolic PH (CTEPH) is classified as group 4 PH by the World Health Organization. The other types are pulmonary arterial hypertension (PAH) due to left heart disease, PH due to lung ...

 


Reviva-FDA Meeting Paves Way for Phase 2 Clinical Trial of RP5063 as a PAH Therapy - Pulmonary Hypertension News



Reviva-FDA Meeting Paves Way for Phase 2 Clinical Trial of RP5063 as a PAH Therapy 
Pulmonary Hypertension News
Reviva Pharmaceuticals has had a meeting with the U.S. Food and Drug Administration that paves the way for a Phase 2 clinical trial of its neurodegenerative therapy RP5063 in pulmonary arterial hypertension. The meeting dealt with an investigational ...

 


Global Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Top Players Pfizer, Gilead Sciences, Eli Lilly ... - Edition Truth



Edition Truth
 
Global Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Top Players Pfizer, Gilead Sciences, Eli Lilly ... 
Edition Truth
The report entitled Global Pulmonary Arterial Hypertension (PAH) Medicine Market: Size, Trends & Forecasts (2017-2021), provides analysis of the global Pulmonary Arterial Hypertension (PAH) Medicine, with detailed analysis of market size and growth ...

 


Nintedanib Reduces Fibrosis and Blood Vessel Remodeling in Mice with Systemic Sclerosis, Study Shows - Scleroderma News



Scleroderma News
 
Nintedanib Reduces Fibrosis and Blood Vessel Remodeling in Mice with Systemic Sclerosis, Study Shows 
Scleroderma News
Systemic sclerosis has a number of manifestations, including vascular remodeling, pulmonary arterial hypertension (PAH), and progressive scarring of skin and organ tissue. Vascular remodeling refers to changes in blood vessel structure, particular ...